Mostrar el registro sencillo del ítem
Continuous-Flow Supercritical CO2 Platform for In-Situ Synthesis and Purification of Small Molecules for Drug Discovery
dc.contributor.author | Alcalde, Sergio | |
dc.contributor.author | Porcar Garcia, Raul | |
dc.contributor.author | De la Puente, María Luz | |
dc.contributor.author | Cumming, Graham | |
dc.contributor.author | Mateos, Carlos | |
dc.contributor.author | García-Losada, Pablo | |
dc.contributor.author | Anta, Cristina | |
dc.contributor.author | Rincón, Juan A. | |
dc.contributor.author | Garcia-Verdugo, Eduardo | |
dc.date.accessioned | 2023-07-03T09:55:10Z | |
dc.date.available | 2023-07-03T09:55:10Z | |
dc.date.issued | 2023-02-03 | |
dc.identifier.citation | ALCALDE, Sergio, et al. Continuous-Flow Supercritical CO2 Platform for In-Situ Synthesis and Purification of Small Molecules for Drug Discovery. Organic Process Research & Development, 2023, vol. 27, no 2, p. 276-285. | ca_CA |
dc.identifier.uri | http://hdl.handle.net/10234/203019 | |
dc.description.abstract | The use of supercritical CO2 (scCO2) as an enabling technology paves the way for an efficient in-line integration of the synthesis and purification of organic molecules. The scCO2 platform presented here provides a streamlined process to produce a diverse family of triazoles, common drug precursors, by 1,3-dipolar copper-catalyzed azide-alkyne cycloaddition (CuAAC, Huisgen reaction), also decreasing the environmental impact by significantly reducing the use of traditional solvents. To further exemplify the potential of this scCO2 platform, the synthesis and purification of rufinamide, a drug used to treat seizures associated with Lennox− Gastaut syndrome, is also reported. | ca_CA |
dc.format.extent | 31 p. | ca_CA |
dc.format.mimetype | application/pdf | ca_CA |
dc.language.iso | eng | ca_CA |
dc.publisher | American Chemical Society | ca_CA |
dc.relation.isPartOf | Organic Process Research & Development, 2023, vol. 27, no 2. | ca_CA |
dc.rights | © 2023 American Chemical Society. "This document is the Accepted Manuscript version of a Published Work that appeared in final form in Organic Process Research and Development, copyright © 2023 American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://pubs.acs.org/doi/full/10.1021/acs.oprd.2c00253." | ca_CA |
dc.rights.uri | http://rightsstatements.org/vocab/InC/1.0/ | ca_CA |
dc.subject | supercritical CO2 | ca_CA |
dc.subject | flow chemistry | ca_CA |
dc.subject | triazole | ca_CA |
dc.subject | 1,3-dipolar cycloaddition | ca_CA |
dc.subject | click chemistry | ca_CA |
dc.subject | in-line/on-line | ca_CA |
dc.title | Continuous-Flow Supercritical CO2 Platform for In-Situ Synthesis and Purification of Small Molecules for Drug Discovery | ca_CA |
dc.type | info:eu-repo/semantics/article | ca_CA |
dc.identifier.doi | https://doi.org/10.1021/acs.oprd.2c00253 | |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | ca_CA |
dc.relation.publisherVersion | https://pubs.acs.org/doi/full/10.1021/acs.oprd.2c00253 | ca_CA |
dc.type.version | info:eu-repo/semantics/acceptedVersion | ca_CA |
project.funder.name | Ministerio de Ciencia e Innovación | ca_CA |
project.funder.name | Universitat Jaume I | ca_CA |
project.funder.name | Generalitat Valenciana | ca_CA |
project.funder.name | Centro de Investigación Lilly S.A. | ca_CA |
oaire.awardNumber | PID2021- 124695OB-C22 | ca_CA |
oaire.awardNumber | UJIB2019-40 | ca_CA |
oaire.awardNumber | AICO/2021/139 | ca_CA |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
QUIO_Articles [701]
Articles de publicacions periòdiques